Paper Details

  1. Home
  2. Paper Details

Citarinostat and Momelotinib co-target HDAC6 and JAK2/STAT3 in lymphoid malignant cell lines: a potential new therapeutic combination.

Author: CivalleroMonica, CosenzaMaria, MarcheselliLuigi, PozziSamantha, SacchiStefano

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

This study investigated the cytotoxic effects of combining citarinostat, an HDAC6 inhibitor, and momelotinib, a JAK/STAT3 inhibitor, in lymphoid cell lines. The combination showed strong cytotoxicity, reducing mitochondrial membrane potential, downregulating Bcl-2 and Bcl-xL, and activating caspases. The combination treatment also inhibited cell viability and clonogenic survival, highlighting its potential for treating lymphoproliferative disorders.
Paper Details　
Original Abstract of the Article :
Histone deacetylase (HDAC) inhibitors represent an encouraging class of antitumor drugs. HDAC inhibitors induce a series of molecular and biological responses and minimal toxicity to normal cells. Citarinostat (Acy-241) is a second generation, orally administered, HDAC6-selective inhibitor. Momeloti...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7244621/

データ提供：米国国立医学図書館（NLM）

A New Duo for Lymphoid Malignancies: Citarinostat and Momelotinib

The fight against cancer is a relentless journey across the vast and challenging desert of disease. This study investigates a potential new therapeutic combination for lymphoid malignancies, two drugs working together to attack cancer cells. The researchers explored the synergistic effects of citarinostat and momelotinib, two drugs targeting distinct pathways involved in cancer cell growth and survival, seeking to enhance the effectiveness of cancer treatment. This study employed a [research methodology] to evaluate the combined effects of citarinostat and momelotinib on lymphoid cell lines. The researchers discovered [key findings] that suggest a promising new approach to treating lymphoid malignancies.

A Synergistic Approach to Combating Cancer

The study found that the combination of citarinostat and momelotinib exhibited significant cytotoxicity against lymphoid cell lines, a potential game-changer in the battle against these cancers. The study found [specific findings] suggesting that targeting both HDAC6 and JAK2/STAT3 pathways simultaneously could be a powerful strategy for combating lymphoid malignancies.

Fighting Cancer Together

This research opens a new avenue in the fight against lymphoid malignancies. The combination of citarinostat and momelotinib could potentially offer a more effective treatment option with potentially fewer side effects. It's important to note that further research is needed to confirm the safety and efficacy of this combination therapy in clinical trials. This study offers a glimpse into the potential of synergistic drug combinations in combating cancer.

Dr. Camel's Conclusion

This study suggests that combining the strengths of citarinostat and momelotinib could be a powerful strategy for combating lymphoid malignancies. Like two camels working together to carry a heavy load across the desert, these drugs synergize to attack cancer cells, offering a new pathway for treatment and a glimmer of hope in the fight against these devastating diseases.

Date :
  1. Date Completed 2021-06-03
  2. Date Revised 2021-07-12
Further Info :

Pubmed ID

32394008

DOI: Digital Object Identifier

PMC7244621

Related Literature

Article Analysis
・Effects of momelotinib
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.